Estats Units - anglès - NLM (National Library of Medicine)

remedyrepack inc. - itraconazole (unii: 304nug5gf4) (itraconazole - unii:304nug5gf4) - itraconazole capsules    are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: 1. blastomycosis, pulmonary and extrapulmonary 2. histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non- meningeal histoplasmosis, and 3. aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin b therapy. specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. itraconazole capsules    are also indicated for the treatment of the following fungal infections in non-immunocompromised patients:  1. onyc

Estats Units - anglès - NLM (National Library of Medicine)

natco pharma usa llc - itraconazole (unii: 304nug5gf4) (itraconazole - unii:304nug5gf4) - itraconazole oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. (see clinical pharmacology: special populations, warnings, and adverse reactions: post-marketing experience for more information.) itraconazole oral solution should not be administered to patients with evidence of ventricular dysfunction such as congestive heart failure (chf) or a history of chf except for the treatment of life-threatening or other serious infections. (see boxed warning, warnings, precautions: drug interactions-calcium channel blockers, adverse reactions: post-marketing experience, and clinical pharmacology: special populations.) coadministration of a number of cyp3a4 substrates are contraindicated with itraconazole. plasma concentrations increase for the following drugs: levaceytlmethadol (levomethadyl), methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergono

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

athlone pharmaceuticals limited - itraconazole - oral solution - triazole derivatives; itraconazole

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ampicillin, quantity: 1 g - injection, powder for - excipient ingredients: - treatment of infections due to susceptible strains of gram-positive and gram-negative organisms. bacteriological studies to determine the organism and its sensitivity should be undertaken.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ampicillin -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydralazine hydrochloride, quantity: 25 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; disodium edetate; purified talc - this product accepted for registration as 'currently supplied' at the time of commencement of the act. variation to pregnancy statement in product information were approved as specified in the letter of 13 august 1992 from dr bijoy varma. indicated for the treatment of drug resistant, moderate to severe, hypertension. this drug is not a first line antihypertensive drug and is better used in combination with other therapy such as a sympatholytic agent and a diuretic. indications as at 28 november 2001 : hypertension (drug resistant, moderate to severe): as supplementary medication for use together with other antihypertensives such as "beta"-blockers and diuretics; the complementary mechanisms of action of such combined therapy enable the drugs to exert their antihypertensive effects at low doses; in addition, unwanted accompanying effects of the individual substances are either partially offset or even cancelled out.

Unió Europea - anglès - EMA (European Medicines Agency)

biomarin international limited - cerliponase alfa - neuronal ceroid-lipofuscinoses - other alimentary tract and metabolism products, - brineura is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (cln2) disease, also known as tripeptidyl peptidase 1 (tpp1) deficiency,

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - tetanus toxoid, quantity: 40 iu; pertussis fimbriae 2 + 3, quantity: 5 microgram; diphtheria toxoid, quantity: 30 iu; poliovirus, quantity: 29 dagu; poliovirus, quantity: 26 dagu; poliovirus, quantity: 7 dagu; pertussis toxoid, quantity: 20 microgram; pertactin, quantity: 3 microgram; pertussis filamentous haemagglutinin, quantity: 20 microgram - injection, suspension - excipient ingredients: polymyxin b sulfate; bovine serum albumin; formaldehyde; phenoxyethanol; glutaral; neomycin; water for injections; polysorbate 80; aluminium phosphate - quadracel is indicated for primary immunisation of children from the age of 2 months to 12 months against diphtheria, tetanus, pertussis, and poliomyelitis.,quadracel is also indicated for the fourth dose for children from 15 months to six years of age who have been immunised previously with three doses of diphtheria, tetanus, pertussis and polio vaccines.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydralazine hydrochloride, quantity: 50 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate; colloidal anhydrous silica; purified talc; disodium edetate; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; indigo carmine; sunset yellow fcf; iron oxide yellow; macrogol 4000; erythrosine - this product accepted for registration as 'currently supplied' at the time of commencement of the act. amended product information (variation to pregnancy statement) was approved as specified in the letter of 13 august 92 from dr bijoy varma. indications as at 28 november 2001 : hypertension (drug resistant, moderate to severe): as supplementary medication for use together with other antihypertensives such as "beta"-blockers and diuretics; the complementary mechanisms of action of such combined therapy enable the drugs to exert their antihypertensive effects at low doses; in addition, unwanted accompanying effects of the individual substances are either partially offset or even cancelled out.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxicillin trihydrate -